Pharmacokinetic Drug-drug Interaction of CKD-330 and D086

Hypertension Clinical Trial

Official title:

Phase I Clinical Trial to Evaluate the Pharmacokinetic Drug-drug Interaction of CKD-330 and D086 in Healthy Male Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03017950
• Other study ID #: 170DDI16017
• Status: Completed
• Phase: Phase 1
• First received: January 10, 2017
• Last updated: July 19, 2017
• Start date: December 2016
• Est. completion date: May 2017

Study information

• Verified date: July 2017
• Source: Chong Kun Dang Pharmaceutical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is examining and comparing the pharmacokinetic drug interaction and safety of both single administration and combination administration of CKD-330 and D086 to healthy male subjects

Description:

An open-label, randomized, multiple-dose, 2-sequence, 2-period, 2-treatment, crossover study

Part1: Examining how D086 affects pharmacokinetics of CKD-330. Part2: Examining how CKD-330 affects pharmacokinetics of D086.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 83
• Est. completion date: May 2017
• Est. primary completion date: March 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 19 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Healthy adult males age of between 19 - 45 on the day of screening.

2. Body mass index(BMI) between 18.0 - 29.0 kg/m^2 and weight = 55kg (Body mass index (BMI) = weight (kg) / height (m)^2)

3. Subjects in good health as determined by physical exams and medical examinations. No congenital or chronic diseases and no abnormal signs determined by medical examinations.

4. Not abnormal or not clinically significant lab values.

5. Subjects who signed informed consent form with good understandings after explanations by investigators.

Exclusion Criteria:

1. No history or presence of clinically significant cardiac, respiratory, neurological, endocrine, metal and renal diseases and liver and kidney diseases.

2. Subjects showing angioedema as an adverse reaction to ACE inhibitors

3. Primary Hyperaldosteronism

4. History or family history of myopathy

5. Subjects with mental diseases or drug addiction

6. Allergic reactions to candesartan or amlodipine or atorvastatin

7. Genetic problems in galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption.

8. Hypotension(SBP =100mmHg or DBP=55mnHg) or hypertension ( SNP = 150mmHg, DBP =95mmHg) on the day of screening

9. Subjects who experienced gastrointestinal diseases or surgeries which can affect absorption of Investigational product

10. Subjects with abnormal lab values at least one below

(AST or ALT>2 fold of upper normal limit, Total bilirubin>2 fold of upper normal limit, CPK>2 fold of upper normal limit, K <3.5mEq/L or >5.5mEq/L, Estimated Glomerular filtration rate<60mL/min/1.73m2 by Modification)

11. Continuous drinking (over 21 units/week, 1 unit= 10g=12.5mL of pure alcohol), heavy smoker(> 10 cigarettes per day) and unable to stop drinking during clinical trials

12. Subjects who previously participated in other clinical trials within 90 days

13. Subjects who donated whole blood within 60 days or donated component blood within 30 days or received blood transfusion within 30 days

14. Subjects who were administered below medications within 30 days (cyclosporin, erythromycin, clarithromycin, lopinavir, ritonavir, itraconazole, ketoconazole, rifampicin, barbiturate : theses medicines could affect absorption, metabolism, distribution and excretion of candesartan,amlodipine and atorvastatin)

15. Subjects who took any prescribed medications or oriental medicines within 14 days, or took any pharmacy medicines within 7 days.

16. Subjects who have taken any diets affecting absorption, metabolism, distribution and excretion of investigational products (especially grapefruit juice).

17. Subjects who are in conditions impossible participating in the clinical trials following other laboratory tests.

18. Unable to use contraceptions.

Related Conditions & MeSH terms

• Hyperlipidemias
• Hyperlipoproteinemias
• Hypertension

Intervention

Drug:
• CKD-330

• D086

• CKD-330 + D086

Locations

Country	Name	City	State
Korea, Republic of	Inha University Hospital	Incheon

Sponsors (1)

Lead Sponsor	Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUCt,ss of Candesartan and Amlodipine		Day6, Day7, Day8, Day9, Day22, Day27, Day28, Day29 and Day30
Primary	AUCt,ss of atorvastatin and 2-hydroxy atorvastatin		Day6, Day7, Day8, Day9, Day22, Day27, Day28, Day29 and Day30